Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) treatments face challenges with non-responders and complications.
• Atypical p38 kinase activity is essential for HCV replication and potentially other viral infections.
• Understanding atypical p38 activation mechanisms by viruses is crucial for developing new therapies.

Purpose of the Study:

• To characterize atypical p38 allosteric modulators (NC compounds) in the context of HCV infection.
• To compare the efficacy of NC compounds against current direct-acting antivirals (DAAs).
• To investigate the broader antiviral potential of NC compounds against other viruses.

Main Methods:

• Treatment of HCV-infected cells with two novel atypical p38 allosteric modulators (NC compounds).
• Comparison of NC compound effects with existing DAAs for HCV and herpesviruses.
• Assessment of viral protein expression and RNA replication following compound treatment.

Main Results:

• NC compounds rapidly attenuated HCV-induced p38 activation, blocking viral protein and RNA replication.
• Both NC compounds demonstrated inhibitory capacity against Human Cytomegalovirus (HCMV) and Herpes Simplex Virus-1 (HSV-1).
• This study is the first to evaluate atypical p38 selective modulators for blocking viral replication.

Conclusions:

• Atypical p38 selective modulators represent a promising strategy to complement existing antiviral treatments.
• Targeting host factors like p38 offers a novel approach to combat viral infections, including HCV, HCMV, and HSV-1.
• While current NC compounds may not be clinically viable, the concept warrants further investigation for therapeutic development.